Top > News Releases

Y's Therapeutics Announced the change of the board members on April 1, 2009


Tokyo, Japan, and San Bruno, CA -April 1st, 2009- Y’s Therapeutics, a privately held biopharmaceutical company, announced that appointing about the Board of directors and the Auditors approved by the 6th shareholders meeting. 　　

　 　

Title	Name
Representative Director & President & CEO	Masanori Murayama
Representative Director & Vice-President & COO	Nobuo Kato
Board director & CFO	Takaharu Itoh
Board director & CSO	Yutaro Kaneko
Board director	Chikao Morimoto
Board director	Hiroyuki Ishikawa

　

　

Title	Name
Permanent auditor	Susumu Yamada
Permanent auditor	Moriaki Mase
Auditor	Sakae Tanaka

About Y's Therapeutics
Y's Therapeutics (http://www.ysthera.com) is a privately held biopharmaceutical company engaged in the R&D of novel therapeutics for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. Y's focuses on the development of preclinical and early-stage clinical projects pursued through research collaborations and in-licensing opportunities from academic institutions and biotech companies. Y's is seeking collaborative relationships, including out-licensing of product rights and creation of joint ventures, for late-stage development, manufacturing and commercialization of its portfolio products. The company currently has several projects in its clinical and preclinical pipeline. Y's has operations in two locations, Y's Therapeutics Co., Ltd., of Tokyo, Japan, and Y's Therapeutics, Inc., of San Bruno, CA.

◈CONTACT◈
Kyoko Harigae
Administrations Department
Y's Therapeutics Co., Ltd.
E-Mail：admin@ysthera.com

Top  |  Site Map  |  Access Map  |  Privacy Policy  |  Terms of Use